arrow_back Back to App

Early Detection of Pediatric Liver Disease and Public Education Program

This Act aims to improve early detection of liver diseases in newborns and children, which can significantly increase chances for effective treatment and transplants. It establishes a public education program for parents and doctors and mandates studies on the effectiveness of current methods and transplant needs, directly impacting the health and safety of the youngest citizens.
Key points
Implementation of a public education program for parents and healthcare providers on early signs of pediatric liver disease and the option of living liver donation.
Mandating a study on the effectiveness of current pediatric liver disease early detection programs and an analysis of wait-list mortality data for liver transplants.
Evaluation of the cost-effectiveness of adding direct-bilirubin screening for biliary atresia and other cholestatic liver diseases to newborn screening panels.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_5355
Sponsor: Rep. Costa, Jim [D-CA-21]
Process start date: 2025-09-15
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_5355.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-09-15.

What are the main provisions?

Key points include:

  • Implementation of a public education program for parents and healthcare providers on early signs of pediatric liver disease and the option of living liver donation.
  • Mandating a study on the effectiveness of current pediatric liver disease early detection programs and an analysis of wait-list mortality data for liver transplants.
  • Evaluation of the cost-effectiveness of adding direct-bilirubin screening for biliary atresia and other cholestatic liver diseases to newborn screening panels.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Costa, Jim [D-CA-21].

What is the latest detailed status?

The latest detailed status is: Sponsor introductory remarks on measure. (CR H4418)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health